Male or females from 12 to 75 years of age with Distal Subungual Onychomycosis (DSO) of at least one of the great toenail(s) affecting 20% to 60% of the target toenail, are needed for this study. Qualified individuals must have positive KOH microscopy and culture for dermatophytes in the target toenail, along with the ability of the great toenail to grow (e.g. reports cutting toenails at least monthly).
Participants will receive investigational topical medication (active study drug) or placebo. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 60 weeks and involve about 8 visits to the study centre.
The following information is from ClinicalTrials.gov
Last Update Posted: December 10, 2023
Moberg Pharma AB
This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)
Condition or Disease:
Ages Eligible for Study:
12 Years and 75 Years (Child)
Sexes Eligible for Study:
Males or females 12 to 75 years of age
Distal subungual onychomycosis of at least one of the great toenail(s) affecting 20% to 60% of the target great toenail (verified by a central blinded assessor before randomization)
Positive KOH microscopy and culture for dermatophytes in the target toenail
Ability of the great toenail to grow (e.g., subject reports cutting toenails at least monthly)
Signed written informed consent and assent (if applicable)
Proximal subungual onychomycosis, superficial white onychomycosis, or significant dystrophy judged clinically by the blinded assessor or by the Investigator that may interfere with clinical evaluation of onychomycosis
Distal subungual onychomycosis where disease involvement has extended into the proximal portion of the target toenail and the unaffected proximal nail is less than 3 mm measured from proximal nail fold
Target toenail thickness more than 3 mm measured at the distal end
“Spike” of onychomycosis extending to eponychium of the target toenail
Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin) or severe onychorrhexis on the target toenail
Nail conditions other than DSO that are known to cause abnormal nail appearance, presence of melanonychia or subungual hematoma that could obscure visualization of nail clearing
Other microbial infections of the target toenail, for example, candida or mold infections without isolation of a dermatophyte
Previous target toenail surgery (within 6 months) with any residual disfigurement that will impact efficacy outcome or will not allow nail to grow normally, as judged by the Investigator
Topical treatment of the toenails with other antifungal medication within 6 weeks before Screening/Visit 1
History of failing oral therapy for onychomycosis within the past 3 years, or inability for nail to appear normal due to trauma, as judged by the Investigator
Systemic use of antifungal treatment within 6 months before Screening/Visit 1
Moderate to severe moccasin tinea pedis that require prolonged topical antifungal treatment or oral antifungal treatment should be excluded. Subjects with symptomatic interdigital tinea pedis or mild moccasin type tinea pedis will be screen failed. However, However, they will be allowed to enter the study after appropriate effective treatment and washout period as per Investigator judgment.
Signs of severe peripheral circulatory insufficiency as determined by significantly diminished/lack of pedal pulse on either foot
Subjects with a current or past history of psoriasis and/or lichen planus
Subjects with poorly controlled (or uncontrolled) diabetes mellitus as determined by HbA1c of > 8%
Known immunodeficiency, i.e., congenital immunodeficiency, acquired immunodeficiency, iatrogenic by immunosuppressive drugs like cytostatics or by radiation therapy or immunomodulatory medications (e.g., TNF inhibitors)
Participation in another clinical trial with an investigational drug or device during the previous 3 months before enrollment/baseline and for the duration of this study
Known allergy to any of the tested treatment products
Female subjects who are pregnant or breastfeeding; or intend to conceive a child during the duration of the study (52 weeks).
Subjects previously randomized to any study involving MOB015B treatment/exposure
History of, or current drug or alcohol abuse that would interfere with a subject’s ability to participate in the study as determined by the Investigator
Psychiatric condition that might limit the participation in the study and/or that lead to the assumption that the subject’s ability to completely understand the consequences of consent is missing
Close affiliation with the Investigator (e.g., a close relative) or persons working at the same study site, or subject who is an employee of the Sponsor/designee
Subjects who are institutionalized because of legal or regulatory order
Any diseases or circumstances in which the subject should not participate in the study in the opinion of the Investigator
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.